CN104784108A - Bambuterol hydrochloride oral liquid composition - Google Patents
Bambuterol hydrochloride oral liquid composition Download PDFInfo
- Publication number
- CN104784108A CN104784108A CN201410023624.5A CN201410023624A CN104784108A CN 104784108 A CN104784108 A CN 104784108A CN 201410023624 A CN201410023624 A CN 201410023624A CN 104784108 A CN104784108 A CN 104784108A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- liquid composition
- bambuterol hydrochloride
- hydrochloride oral
- kwd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a bambuterol hydrochloride oral liquid composition. The bambuterol hydrochloride oral liquid composition comprises, by mass, 0.5-1.5% of bambuterol hydrochloride, 0.5-1.5% of sodium benzoate, 0.1-0.5% of water-soluble edible essence, 0.05-0.15% of stevioside, 0.2-0.8% of 10% dilute hydrochloric acid and 94-98% of water for injection. The above prescription design is accurate and reasonable, and the above obtained oral liquid has the advantages of small taking dosage, fast absorption, stable quality and easy preservation, and is suitable for industrial production.
Description
Technical field
The present invention relates to the configuration of a kind of medicine containing organic effective component product, particularly a kind of KWD-2183 oral administration solution compositions.
Background technology
KWD-2183 (Bambuterol Hydrochloride Tablet), chemical name is: 1-[two-(3 ', 5 '-N, N-diformazan carbamoyloxy group) phenyl]-2-N-t-butylaminoethyl hydrochlorate.This product is the prodrug of optionally beta 2 receptor agonist-terbutaline, and after oral absorption under the effect of enzyme, metabolism is terbutaline.The beta 2 receptor of terbutaline primary activation bronchial smooth muscle, thus bronchial smooth muscle is relaxed.Indication is bronchial asthma, chronic asthmatic bronchitis, obstructive emphysema and other pulmonary disease with bronchospasm.
Chinese patent application CN201210098201.0 discloses the preparation technology of a kind of KWD-2183 and intermediate thereof; Chinese patent application CN200310121927.2 discloses a kind of dripping pills of bambuterol hydrochloride and preparation method thereof; Chinese patent application CN200310111140.8 discloses a kind of Oral disintegrating tablet of bambuterol hydrochloride and its preparation method.But oral liquid have taking dose little, absorb the advantages such as very fast, steady quality, easy to carry and use, easy preservation, be especially applicable to suitability for industrialized production.
Summary of the invention
The object of the invention is to solve above-mentioned deficiency, a kind of KWD-2183 oral administration solution compositions is provided.
The technical scheme realizing the object of the invention is: a kind of KWD-2183 oral administration solution compositions, and the mass percent of each component is as follows:
Above-mentioned KWD-2183 oral administration solution compositions, the mass percent of each component is as follows:
Above-mentioned KWD-2183 oral administration solution compositions, the mass percent of each component is as follows:
Beneficial effect of the present invention: Formulation of the present invention is accurately reasonable, the advantages such as gained oral liquid taking dose is little, absorption is very fast, steady quality, easily preservation, are applicable to suitability for industrialized production.
Detailed description of the invention
(embodiment 1) takes each main ingredient according to following proportioning, total amount 1000 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
(embodiment 2) takes each main ingredient according to following proportioning, total amount 1000 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
(embodiment 3) takes each main ingredient according to following proportioning, total amount 600 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
(embodiment 4) takes each main ingredient according to following proportioning, total amount 600 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
(embodiment 5) takes each main ingredient according to following proportioning, total amount 600 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
(embodiment 6) takes each main ingredient according to following proportioning, total amount 600 grams:
1000 are made according to operations such as configuration, sterilizing, cleaning, embeddings.
Above-described specific embodiment; object of the present invention, technical scheme and beneficial effect are further described; be understood that; the foregoing is only specific embodiments of the invention; be not limited to the present invention; within the spirit and principles in the present invention all, any amendment made, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (3)
1. a KWD-2183 oral administration solution compositions, is characterized in that the mass percent of each component is as follows:
2. KWD-2183 oral administration solution compositions according to claim 1, is characterized in that: the mass percent of each component is as follows:
3. KWD-2183 oral administration solution compositions according to claim 1, is characterized in that: the mass percent of each component is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410023624.5A CN104784108A (en) | 2014-01-17 | 2014-01-17 | Bambuterol hydrochloride oral liquid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410023624.5A CN104784108A (en) | 2014-01-17 | 2014-01-17 | Bambuterol hydrochloride oral liquid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104784108A true CN104784108A (en) | 2015-07-22 |
Family
ID=53549616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410023624.5A Pending CN104784108A (en) | 2014-01-17 | 2014-01-17 | Bambuterol hydrochloride oral liquid composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784108A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110898003A (en) * | 2019-12-09 | 2020-03-24 | 岳阳新华达制药有限公司 | Novel bambuterol hydrochloride oral solution and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210464A (en) * | 1996-12-20 | 1999-03-10 | 阿斯特拉公司 | Aqueous formulation comprising bambuterol and use thereof |
| EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
-
2014
- 2014-01-17 CN CN201410023624.5A patent/CN104784108A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210464A (en) * | 1996-12-20 | 1999-03-10 | 阿斯特拉公司 | Aqueous formulation comprising bambuterol and use thereof |
| EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
Non-Patent Citations (1)
| Title |
|---|
| 夏锡荣，等: "盐酸班布特罗口服液治疗儿童支气管哮喘的疗效评价", 《江苏医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110898003A (en) * | 2019-12-09 | 2020-03-24 | 岳阳新华达制药有限公司 | Novel bambuterol hydrochloride oral solution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915592A2 (en) | gpr119 receptor agonist compound, process for preparing the compound, pharmaceutical composition comprising it, use thereof and method for the treatment or prophylaxis of type II diabetes mellitus | |
| FI3335707T3 (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
| WO2007005633A8 (en) | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate | |
| TW200607508A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | |
| JP6662312B2 (en) | Solid composition | |
| MX336225B (en) | Compositions comprising salbutamol sulphate. | |
| CN102640750A (en) | Special adjuvant of glyphosate potassium salt aqueous solution and salt aqueous solution using same | |
| RU2019110980A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION | |
| CN103893116B (en) | A kind of Bisolvon oral liquid compositions | |
| WO2010066810A8 (en) | Transdermal pharmaceutical compositions comprising a serm | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| CN104784108A (en) | Bambuterol hydrochloride oral liquid composition | |
| CN102488711A (en) | Method for preparing compound paracetamol and amantadine hydrochloride tablet | |
| WO2014006636A3 (en) | Stable compositions of fesoterodine | |
| CN104622854A (en) | Tablet containing ambroxol hydrochloride and salbutamol sulfate | |
| WO2011063775A3 (en) | Pectin complexes of sartans and pharmaceutical compositions based thereon | |
| CN102526104B (en) | Compound dermatophytosis treatment liquid medicine and preparation method thereof | |
| TN2013000425A1 (en) | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | |
| RU2013141465A (en) | METHOD FOR PRODUCING JELLY FRUIT MARMELADE | |
| MX2015007347A (en) | Gel compositions. | |
| CN104644580A (en) | Pharmaceutical composition of teneligliptin | |
| CN105357966A (en) | Method and products for enhancing drug and dietary supplement bioavailability | |
| CN104784128A (en) | Bambuterol Hydrochloride tablet composition | |
| CN103893120A (en) | Fluticasone propionate spraying agent with improved stability | |
| CN102579281A (en) | Perfume |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |